(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 73.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.81%.
Calcimedica's earnings in 2025 is -$23,060,000.On average, 6 Wall Street analysts forecast CALC's earnings for 2025 to be -$24,838,977, with the lowest CALC earnings forecast at -$24,288,537, and the highest CALC earnings forecast at -$25,115,638. On average, 6 Wall Street analysts forecast CALC's earnings for 2026 to be -$27,998,965, with the lowest CALC earnings forecast at -$30,219,459, and the highest CALC earnings forecast at -$25,266,937.
In 2027, CALC is forecast to generate -$43,945,883 in earnings, with the lowest earnings forecast at -$42,222,515 and the highest earnings forecast at -$45,238,409.